Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia

NCT05576181 is registered in ClinicalTrials.gov with Fundamenta Therapeutics, Ltd. as lead sponsor.

NCT NCT05576181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05576181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia
Lead sponsor
Fundamenta Therapeutics, Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
October 15, 2022
Completion date
July 22, 2025
Enrollment
19 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic, car-t, protein sequestration, non-gene edited